• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed

    2/25/21 4:06:00 PM ET
    $BFRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BFRA alert in real time by email
    SC 13D/A 1 d127025dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON D.C.

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)

     

     

    BIOFRONTERA AG

    (Name of Issuer)

    Ordinary Shares, with no par value, €1.00 nominal value per share

    (Title of Class of Securities)

    09075G105**

    (CUSIP Number)

    Maruho Deutschland GmbH

    Hemmelrather Weg 201, Haus 2

    51377 Leverkusen, Germany

    Telephone: +49(0)214-892201-0

    Copies to:

    John J. Harrington

    Baker & Hostetler LLP

    127 Public Square, Suite 2000

    Cleveland, Ohio 44114-1214

    Telephone: (216) 621-0200

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    February 24, 2021

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    **

    The Ordinary Shares have no CUSIP number. The CUSIP number for the ADSs, each representing two Ordinary Shares, is 09075G105.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 09075G105   SCHEDULE 13D

     

      1   

    NAME OF REPORTING PERSON

     

    Maruho Co., Ltd.

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

        

      4  

    SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

    WC

      5  

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)  ☐

     

        

      6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Japan

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

          7     

    Sole Voting Power

     

    13,399,965

          8     

    Shared Voting Power

     

    0

          9     

    Sole Dispositive Power

     

    13,399,965

        10     

    Shared Dispositive Power

     

    0

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    13,399,965

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    13  

    PERCENTAGE OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    23.63% (1)

    14  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    (1)

    Based upon 56,717,385 shares outstanding as reported in the Issuer’s Form 6-K filed on February 25, 2021.


    CUSIP No. 09075G105   SCHEDULE 13D

     

      1   

    NAME OF REPORTING PERSON

     

        Maruho Deutschland GmbH

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

        

      4  

    SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

    AF

      5  

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)  

     

    ☐

      6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Germany

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

          7     

    Sole Voting Power

     

    13,399,965

          8     

    Shared Voting Power

     

    0

          9     

    Sole Dispositive Power

     

    13,399,965

        10     

    Shared Dispositive Power

     

    0

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    13,399,965

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    13  

    PERCENTAGE OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    23.63 % (1)

    14  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    (1)

    Based upon 56,717,385 shares outstanding as reported in the Issuer’s Form 6-K filed on February 25, 2021.


    CUSIP No. 09075G105

       SCHEDULE 13D

     

    SCHEDULE 13D

    This Amendment No. 2 (“Amendment No. 2”) amends and supplements the Schedule 13D (the “Initial Schedule 13D” and together with Amendment No. 1 and Amendment No. 2, the “Schedule 13D”) filed with the Securities and Exchange Commission on July 24, 2019 and amended by Amendment No. 1, dated August 29, 2019 (“Amendment No. 1”), by Maruho Co., Ltd. (“Maruho Japan”) and its wholly-owned subsidiary, Maruho Deutschland GmbH (“Maruho Germany” and together with Maruho Japan, the “Reporting Persons”) with respect to the Ordinary Shares, with no par value, €1.00 nominal value per share (the “Shares”), of Biofrontera AG (“Biofrontera” or the “Issuer”). Capitalized terms used herein and not otherwise defined in this Amendment No. 2 shall have the meanings set forth in the Initial Schedule 13D. This Amendment No. 2 amends Items 2, 5, 6 and 7 to the extent set forth below.

    Item 2. Identity and Background.

    Item 2 of the Schedule 13D is hereby supplemented as follows:

    The name, business address, principal occupation and citizenship of (1) each executive officer and member of the Board of Directors of Maruho Japan and (2) each managing director of Maruho Germany is set forth on Schedule 1 hereto.

    During the last five (5) years, none of the Reporting Persons or the persons listed on Schedule 1 has been: (1) convicted in a criminal proceeding (excluding violations or similar misdemeanors) or (2) party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgement, decree, or final order enjoining future violations of, or prohibiting, or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    Item 5. Interest in Securities of the Issuer.

    Item 5 of the Schedule 13D is hereby amended and restated in its entirety to read as follows:

    (a) – (b) The Reporting Persons had, as of February 24, 2021, sole power to vote or to direct the vote and sole power to dispose or to direct the disposition of 13,399,965 Shares, representing 23.63% of the 56,717,385 outstanding Shares as reported in the Issuer’s Form 6-K filed on February 25, 2021 (after giving effect to the capital increase referenced in Item 6 below). The information disclosed under Item 6 of this Amendment No. 2 is incorporated into this Item 5 by reference. Maruho Japan is the indirect beneficial owner of such Shares and its wholly-owned subsidiary Maruho Germany is the direct beneficial owner of such Shares. Mr. Kenichi Owada and Mr. Takaharu Kato, Managing Directors of Maruho Germany, each have sole voting and dispositive power over a single Share.

    (c) Other than as described in Item 6 below and Mr. Takaharu Kato’s purchase of a single Share on February 11, 2021 for EUR 3.17, there have been no transactions in the Shares in the past 60 days.

    (d) – (e) Not applicable.

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    Item 6 of the Schedule 13D is hereby supplemented as follows:

    On February 8, 2021, the Issuer commenced a preemptive rights offering of new Shares to the Issuer’s existing holders of Shares and an offering of American Depositary Shares (“ADSs”) as part of an increase of the Issuer’s share capital.

    To facilitate the Issuer’s offering of ADSs, on February 5, 2021, Maruho Germany entered into a share loan agreement (the “Share Loan”) with Quirin Privatbank AG, Frankfurt am Main, Germany (the “Share Loan Agent”). Maruho Germany also entered into a related agreement with the Issuer, whereby it agreed not to exercise its right to participate in the Issuer’s preemptive rights offering and transferred that right to participate to the Share Loan Agent. Pursuant to the Share Loan, Maruho Germany agreed to loan to the Share Loan Agent up to 8,969,870 Shares in order to facilitate the ADS offering and delivery of the underlying Shares.


    On February 24, 2021, 2,765,423 Shares (the “Loaned Shares”) were loaned by Maruho Germany to the Share Loan Agent pursuant to the Share Loan. To the extent ADSs were placed in the offering, the Loaned Shares will be used as underlying Shares for these ADSs. To repay and satisfy the Share Loan, the Share Loan Agent subscribed for a number of newly issued Shares equal to the number of Loaned Shares to be used for the ADS offering. These newly issued Shares together with any remaining Loaned Shares not used for the ADS offering (if any) are currently expected to be (re-)transferred to Maruho Germany in repayment and satisfaction in full of the Share Loan on March 1, 2021 and no later than March 5, 2021. Because of the short-term nature of the Share Loan and Maruho Germany’s right to request that the Share Loan Agent grants Maruho Germany a power of attorney to vote the Loaned Shares, Maruho Germany retained beneficial ownership of the Loaned Shares.

    Item 7. Material to be Filed as Exhibits.

    Item 7 of the Schedule 13D is hereby supplemented as follows:

     

    Exhibit
    No.

      

    Description

    1    Share Loan Agreement, dated February  5, 2021, between Maruho Deutschland GmbH and Quirin Privatbank AG (incorporated by reference to Exhibit 99.3 to the Issuer’s Form 6-K filed on February 8, 2021).


    SIGNATURE

    After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete, and correct.

     

    Dated: February 25, 2021    

    MARUHO CO., LTD.

       

    By:

     

    /s/ Atsushi Sugita

       

    Name:

     

    Atsushi Sugita

       

    Title:

     

    President and CEO

       

    MARUHO DEUTSCHLAND GMBH

       

    By:

     

    /s/ Junichi Hamada

       

    Name:

     

    Junichi Hamada

       

    Title:

     

    Managing Director


    SCHEDULE I

    The following table sets forth the name, principal occupation and citizenship for each executive officer and member of the Board of Directors of Maruho Japan. The business address of each listed person is 1-5-22 Nakatsu, Kita-ku, Osaka, Japan.

     

    Name

      

    Principal Occupation

      

    Citizenship

    Koichi Takagi   

    Chairman of the Board, Maruho Co., Ltd.

    Representative Director of the Board, Maruho Co., Ltd.

       Japan
    Atsushi Sugita   

    President & Chief Executive Officer, Maruho Co., Ltd.

    Representative Director of the Board, Maruho Co., Ltd.

       Japan
    Yasuyuki Ishimaru   

    Director of the Board, Maruho Co., Ltd.

    Executive Corporate Officer, Maruho Co., Ltd.

       Japan
    Yasuhiko Kito   

    Director of the Board, Maruho Co., Ltd.

    Senior Corporate Officer, Maruho Co., Ltd.

       Japan
    Masahiro Takeda   

    Director of the Board, Maruho Co., Ltd.

    Senior Corporate Officer, Maruho Co., Ltd.

       Japan
    Takashi Kitagawa   

    Director of the Board, Maruho Co., Ltd.

    Senior Corporate Officer, Maruho Co., Ltd.

       Japan
    Junichi Hamada   

    Director of the Board, Maruho Co., Ltd.

    Senior Corporate Officer, Maruho Co., Ltd.

    Managing Director, Maruho Deutschland GmbH

       Japan
    Akihiro Watanabe   

    Representative Director, GCA Corporation, Tokyo, Japan

    Director of the Board, Maruho Co., Ltd.

       Japan
    Yoshihiko Akagi   

    Representative Director, AKAGI TRADING CO., LTD, Kobe, Japan

    Representative Director, DiaSys Japan K.K., Kobe, Japan

    Director of the Board, Maruho Co., Ltd.

       Japan
    Toshio Asano   

    Standing Counsellor, Asahi Kasei Corp., Tokyo. Japan

    Director of the Board, Maruho Co., Ltd.

       Japan

    The following table sets forth the name, principal occupation and citizenship for each managing director of Maruho Germany. The business address of each listed person is Hemmelrather Weg 201, Haus 2, 51377 Leverkusen, Germany.

     

    Name

      

    Principal Occupation

      

    Citizenship

    Junichi Hamada   

    Managing Director, Maruho Deutschland GmbH

    Director of the Board, Maruho Co., Ltd.

    Senior Corporate Officer, Maruho Co., Ltd.

       Japan
    Kenichi Owada    Managing Director, Maruho Deutschland GmbH    Japan
    Takaharu Kato    Managing Director, Maruho Deutschland GmbH    Japan
    Get the next $BFRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BFRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BFRA
    Financials

    Live finance-specific insights

    See more
    • Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021

      Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2021. Key financial figures and business performance for the nine months ended September 30, 2021 In EUR thousands9M 20219M 2020ChangeQ3 2021Q3 2020ChangeRevenue18,473 20,829 (11)%5,379 4,713 14%thereof from product sales18,473 14,337 29%5,379 4,661 15%Gross profit on sales15,761 18,262 (14)%4,680 3,637 29%Research and development costs(4,516)(3,403)33%(1,595)(1,014)57%General and administrative costs(7,557)(6,882)10%(2,004)(2,410)19%S

      11/17/21 5:00:00 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera AG: Conference call to discuss third quarter 2021 financial results to be held on November 18, 2021

      Leverkusen, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, will be releasing its financial results for the first nine months ended September 30, 2021 on Wednesday, November 17, 2021. Conference calls for shareholders and interested investors will be held on Thursday, November 18, 2021, at the following times: In German, November 18, 2021 at 10:00 am CET (4:00 am ET)Dial-in number Germany: +49 69201744220Conference code: 35058739# In English, November 18, 2021 at 2:00 pm CET (8:00 am ET)Dial-in number USA: +1 8774230830Dial-in number UK: +44 2030092470Conference co

      11/9/21 5:45:49 AM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera AG: Conference call to discuss half-year 2021 financial results to be held on August 20, 2021

      Leverkusen, Germany, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2021 on Thursday, August 19, 2021. Conference calls for shareholders and interested investors will be held on Friday, August 20, 2021, at the following times: In German, August 20, 2021 at 10:00 am CEST (4:00 am EST)Dial-in number Germany: +49 69201744220Conference code: 63828444# In English, August 20, 2021 at 2:00 pm CEST (8:00 am EST)Dial-in number USA: +1 8774230830Dial-in number UK: +44 2030092470Conference code: 78540812# Plea

      8/12/21 8:55:00 AM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRA
    SEC Filings

    See more
    • SEC Form EFFECT filed by Biofrontera AG

      EFFECT - Biofrontera AG (0001712641) (Filer)

      3/14/22 12:15:06 AM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15F-12B filed by Biofrontera AG

      15F-12B - Biofrontera AG (0001712641) (Filer)

      3/9/22 4:27:42 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POS AM filed by Biofrontera AG

      POS AM - Biofrontera AG (0001712641) (Filer)

      3/9/22 2:35:54 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs

      Leverkusen, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera AG (the "Company") (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))), an international biopharmaceutical company, decided today its American Depositary Shares ("ADS") should be delisted from the Nasdaq Capital Market ("Nasdaq") and its reporting obligations with the Securities and Exchange Commission ("SEC") should be deregistered and terminated. The main purpose of the delisting is to reduce complexity in financial reporting and administrative costs. Biofrontera AG intends to maintain an amended ADS program on a Level I basis, which will allow investors to continue to hold their securities in the form of ADSs and trade the

      2/14/22 2:05:00 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera AG announces mediation results

      Leverkusen, Germany, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (OTC:BFFTF) has been in mediation proceedings with Mr. Wilhelm K. T. Zours and Deutsche Balaton AG for a year in order to find a solution for the settlement of legal disputes and other differences (see ad hoc announcement of September 11, 2020). Mr. Zours is an indirect major shareholder of Biofrontera AG, holding the shares in Biofrontera AG through various companies (hereinafter "Deutsche Balaton Group"). Another major shareholder is Maruho Deutschland GmbH, a subsidiary of Maruho Co. Ltd, Japan. At the upcoming Annual General Meeting of Biofrontera AG on December 14, 2021

      11/19/21 8:45:00 AM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021

      Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2021. Key financial figures and business performance for the nine months ended September 30, 2021 In EUR thousands9M 20219M 2020ChangeQ3 2021Q3 2020ChangeRevenue18,473 20,829 (11)%5,379 4,713 14%thereof from product sales18,473 14,337 29%5,379 4,661 15%Gross profit on sales15,761 18,262 (14)%4,680 3,637 29%Research and development costs(4,516)(3,403)33%(1,595)(1,014)57%General and administrative costs(7,557)(6,882)10%(2,004)(2,410)19%S

      11/17/21 5:00:00 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Biofrontera AG (Amendment)

      SC 13D/A - Biofrontera AG (0001712641) (Subject)

      2/25/22 4:01:31 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Biofrontera AG (Amendment)

      SC 13D/A - Biofrontera AG (0001712641) (Subject)

      12/21/21 4:01:09 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Biofrontera AG (Amendment)

      SC 13D/A - Biofrontera AG (0001712641) (Subject)

      11/29/21 4:01:24 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Biofrontera Ag claimed ownership of 8,000,000 shares

      3 - Biofrontera AG (0001712641) (Reporting)

      10/28/21 9:46:54 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care